The landscape of HCV treatments is changing dramatically. At the beginning of this new era, we highlight the challenges for HCV therapy by assessing the long-term epidemiological trends in treatment uptake, efficacy and mortality among HIV/HCV-coinfected people since the availability of HCV therapy. Methods: We included all SHCS participants with detectable HCV RNA between 2001 and 2013. To identify predictors for treatment uptake uni-and multivariable Poisson regression models were applied. We further used survival analyses with Kaplan-Meier curves and Cox regression with drop-out as competing risk. Results: Of 12,401 participants 2107 (17%) were HCV RNA positive. Of those, 636 (30%) started treatment with an incidence of 5.8/100 person years (PY) (95% CI 5.3-6.2). Sustained virological response (SVR) with pegylated interferon/ribavirin was achieved in 50% of treated patients, representing 15% of all participants with replicating HCV-infection. 344 of 2107 (16%) HCV RNA positive persons died, 59% from extrahepatic causes. Mortality/100 PY was 2.9 (95% CI 2.6-3.2) in untreated patients, 1.3 (1.0-1.8) in those treated with failure, and 0.6 (0.4-1.0) in patients with SVR. In 2013, 869/2107 (41%) participants remained HCV RNA positive.
Introduction
The treatment of hepatitis C virus (HCV) infection in HIV-infected patients has changed dramatically in the last decades. Before 1990, HCV-infection was incurable. Subsequently, sustained viral response (SVR) was only about 10% with interferon monotherapy [1] . After 2000, and until recently, the pegylated interferon and ribavirin (pegIFN/RBV) combination therapy improved outcome substantially, but still resulted in modest SVR of 14-29% for genotype 1, and 44-73% for genotypes 2 or 3 [2] [3] [4] . Although successful treatment of chronic HCV-infection decreased liver-specific and all-cause mortality [5, 6] , rates of treatment uptake in the HIV-coinfected population were low [7] . Barriers to start treatment included comorbid medical and psychiatric conditions, active substance abuse with the inability to adhere to complex HCV treatment regimens, expected adverse effects of or contraindications for HCV combination therapy, and uncontrolled HIV disease (reviewed in [7] ).
With the availability of direct-acting antivirals (DAAs), the landscape of HCV treatment is changing rapidly. New treatment options with high cure rates for HIV/HCV-coinfected patients are now available or will be approved shortly. At the beginning of this new era, documentation of the long-term epidemiological trends, treatment uptake, outcome and mortality of HCV-infections is important to adequately assess the impact of new therapies. Moreover, physicians and public health authorities need information on the proportion of patients with replicating HCV-infection, on HCV genotype distribution and on liver-related complications in representative populations. This information is key to define the most urgent treatment priorities, and to optimally invest the available resources in order to reduce HCV-related mortality in HIV-infected patients.
The Swiss HIV Cohort Study (SHCS) offers an ideal platform to study the natural course of HCV-infection and long-term influence of HCV treatments in a nationwide representative population of HIV-infected patients. We aimed to (i), assess the changes in epidemiology, clinical course and therapy of HCV-infections between 2001 and 2013, and (ii), to characterize the population who remains eligible for the new HCV treatment options by the end of 2013.
Patients and methods

Swiss HIV cohort study
The SHCS is an ongoing, prospective cohort study that continuously enrolls and observes HIV-infected adults at five university outpatient clinics, two large district hospitals, affiliated regional hospitals, and private practices, since 1988. This nationwide cohort covers 69% of all patients living with AIDS, and 75% of persons receiving antiretroviral therapy (ART) in Switzerland [8, 9] . Demographic, clinical and laboratory data are collected at registration and every six months thereafter using a standard protocol. The protocol was approved by local ethical review boards, and written informed consent was obtained from all participants.
The indication for HCV therapy and treatment monitoring is provided by HIV-and HCV-trained infectious diseases specialists in the same clinical setting as HIV therapy.
Laboratory measurements and data collection
All SHCS participants are routinely screened for HCV antibodies at study entry. Since 1998, serology was repeated every second year of follow-up in participants with previously negative results. Starting routinely in 2002, quantitative HCV RNA measurements and HCV genotype determination were undertaken in HCV-seropositive persons.
In addition to the information retrieved from the SHCS database, detailed information on HCV-infection, on treatment history and outcomes was obtained by retrospective chart review using a structured questionnaire. Deaths were classified as liver-related (including cirrhosis and liver cancer), HIV/AIDS, cardiovascular, non-liver cancer, sepsis due to any cause (including bacterial and candida septicemia, endocarditis, pneumonia, bacterial meningitis), drug-related, and other causes. All events neither related to HCV-infection nor to other liver diseases were classified as extrahepatic events. Events involving other organs than the liver, but clearly associated with liver cirrhosis, including variceal hemorrhage and hepatorenal syndrome, were classified as liver-related.
Patients' selection
All SHCS participants with at least one study visit between 1 January 2001, the date when pegIFN became available for HIV/HCV-coinfected patients in Switzerland, and 31 December 2013 were included in these analyses. Patients treated with standard IFN (with or without RBV) were excluded (n = 22).
Definitions
HCV treatment outcomes were defined as SVR, relapse, or nonresponse, according to standard definitions [10] . SVR was defined as at least one negative HCV RNA test P12 weeks after the end of treatment [11] . Patients without an HCV RNA test after the end of treatment were classified as nonresponders if their HCV RNA remained positive during treatment (n = 8), and were excluded if their HCV RNA was undetectable at the end of treatment or at the last on treatment test (n = 6), or if they had no available on treatment HCV RNA value (n = 22). A treatment course was considered terminated if pegIFN was discontinued for P30 days.
Liver fibrosis stage was derived from liver biopsy using the Metavir scoring system [12] 
Treatment efficacy analyses
Treatment outcomes were analyzed separately for genotype 1 and 4, respectively 2 and 3, because of the different SVR rates by genotype. Early therapies in acute HCV-infections and DAA treatment regimens (in Switzerland available after November 2011, n = 57) were not considered for the analyses of treatment outcome. In patients with multiple treatment courses, only the first course was evaluated for treatment uptake and outcome. Time trends were analyzed using non-parametric tests for trend.
Survival analyses
Survival analyses of participants with at least two follow-up visits were performed using Kaplan-Meier curves and Cox regression with drop-out as competing risk. Baseline was defined as the date of the first visit after 1 January 2001. We used Stata/SE 13.1 (StataCorp, College Station, Texas, USA) for all analyses.
Results
Study population
Of 12,401 SHCS participants followed between 1 January 2001 and 31 December 2013, 2956 (23.8%) were HCV antibody positive, and 2107 (17.0%) were HCV RNA positive (Fig. 1) . In 415 patients HCV RNA was not available (Fig. 1 ). Of those, 42.0% died and 39.5% left the cohort in the first years after the approval of pegIFN/RBV therapy in Switzerland, in a time period where HCV RNA was not collected systematically. HCV RNA tested vs. HCV RNA untested patients did not differ regarding sex, age, and HIV transmission mode (all p >0.1). HCV RNA positive patients had in 43% genotype 1, in 3% genotype 2, in 25% genotype 3, in 16% genotype 4, and in 0.1% genotype 6 infections. The proportion of men was 69% and median age at registration was 33 years. The distribution of HIV transmission group was 69% intravenous drug users (IDU), 16% heterosexuals and 12% men who have sex with men (MSM). The treatment providers were university centers (62%), affiliated hospitals (12%), and private HIV practitioners (27%) ( Table 1) . Of 2519 HCV-seropositive patients with available HCV RNA values 491 (19.5%) cleared HCV spontaneously.
HCV treatment uptake
The 2107 HCV RNA positive participants contributed to 10,764 PY. 1471 (70%) participants never received HCV therapy, whereas 636 (30%) started treatment between 2001 and 2013, resulting in an overall incidence of 5.8/100 PY (95% CI 5.3-6.2); 6.6 (5.7-7. Characteristics of HCV treated and untreated participants at date of treatment start or date of last follow-up visit are displayed in Table 1 . Untreated patients missed more appointments during the follow-up period (FUP). Mean number of missed appointments/year during FUP for untreated vs. treated patients were 0.05 and 0.02, respectively (p <0.001). In the multivariable model, predictors for treatment uptake were genotype 3, younger age, MSM, CD4 cell count >200 cells/ll, absence of psychiatric disorders, and being under the care of an HIV practitioner. Treatment uptake did not change significantly between time periods (Table 2) .
Of 636 treated patients, 11% were treated twice, and 2% had P3 treatment cycles. 144 (6.8%) of 2107 HCV RNA positive infections were incident infections. Of these, 39 (27%) were treated early within six months after first HCV diagnosis. 
Mortality
Mortality (per 100 PY) was 2.9 (95% CI 2.6-3.2) in HCV-coinfected participants who were not HCV treated, 1.3 (1.0-1.8) in treated patients with treatment failure, 0.6 (0.4-1.0) in treated patients with SVR, and 0.9 (0.8-1.0) in participants without HCV-coinfection. This pattern was confirmed in Cox regression with drop-out as competing risk, resulting in subhazard ratios of 3.0 (95% CI 2.6-3.4, p <0.001) for untreated, 1.6 (1.2-2.2, p = 0.001) for treated patients without SVR, and 0.8 (0.5-1.3, p = 0.3) for patients with SVR, compared with participants not coinfected with HCV. Subhazard ratio for treated patients without SVR vs. SVR was 2.1 (1.2-3.6, p = 0.009), and for untreated vs. treated participants with failure 1.9 (1.4-2.5, p <0.001) (Fig. 2) . Baseline characteristics of HCV negative, HCV positive treated and untreated patients are shown in the Supplementary  Table S1 .
Among the HCV-untreated participants, a total of 295/1471 (20.1%) died. Causes of death were liver-related (38.0%), HIV/AIDS (17.6%), sepsis (15.0%), and cardiovascular diseases (12.4%) in 193 participants with known causes of death. In the treated group 49/636 (7.7%) patients died; causes were liver-related (59.4%), sepsis (19.4%), HIV-AIDS (8.3%), and cardiovascular diseases (5.6%) in 32 patients with known causes of death.
Temporal changes in the characteristics of the HCV-positive population a replicating HCV-infection over time. (Fig. 3) .
Discussion
This is one of the largest nationwide community based HIV cohort studies describing the long-term changes in epidemiology, treatment uptake, efficacy, and mortality of HCV-coinfection since the availability of HCV treatment. We found that of 12,401 cohort participants 24% were HCV-seropositive and 17% were HCV RNA positive. Of those with replicating HCV-infection, 30% were treated and 15% were cured during a follow-up period of thirteen years. During the observation period 16% of participants with active HCV-infection died, 59% due to extrahepatic complications. 41% remained with replicating HCV-infection. Taken together, only a minority of HCV-infected participants benefited from HCV therapy in the last two decades while a large part of patients still awaits treatment. By the end of 2013, 14% to 20% of coinfected individuals had advanced fibrosis or cirrhosis and thus an urgent indication for therapy; 20% of participants are treatment experienced and may thus be more difficult to cure even with DAA therapies. However, most patients did not die from liver-related complications, irrespective of treatment history. This indicates the importance of integrative care of HIV/HCV-coinfected individuals including the diagnosis and treatment of somatic and psychiatric disorders. The incidence of treatment uptake of 5.8 per 100 PY and a treatment rate of 30% in the SHCS is similar to recent data from other European cohorts. In the EuroSIDA study treatment incidence ranged between 2.22 and 5.93/100 PY between 2001 and 2010 [16] , and in a German and Swedish HIV/HCV cohort treatment rates were 40% and 25%, respectively [17, 18] . In a large US cohort of veterans only 12% of monoinfected patients received therapy between 2000 and 2005 [19] ; in coinfected populations treatment uptake was even lower [20, 21] . Predictors for treatment uptake, including genotype 3, MSM, younger age, no psychiatric disorders and controlled HIV-infection, indicate that therapy was started in the easier-to-treat patients. This is consistent with data from other studies [7, 16, 18] . Treatment uptake over time did not change significantly in our cohort.
The overall SVR rates of 35.2% in genotypes 1 and 4, respectively 68.4% in genotypes 2 and 3 are comparable to cure rates achieved in randomized controlled trials in coinfected patients [ [2] [3] [4] . In genotypes 1 and 4, SVR significantly increased over time.
The use of weight-based ribavirin and extended treatment duration after 2008 together with increased provider experience might have resulted in higher cure rates in the more difficult-to-treat genotypes. The decision to treat after the discovery of IL28B haplotype 2009 was not influenced relevantly by this parameter. In the SHCS, IL28B was determined mainly in the frame of retrospective studies [22] and was only very rarely used in clinical decision algorithms. Mortality was 16% in our HIV/HCV-coinfected cohort. This is comparable to the mortality rate of 14% in a US hepatitis C cohort with 3% coinfected patients [23] . SVR was strongly associated with lower mortality rates in comparison to treated patients with failure. This is in accordance with recent studies finding a reduction of mortality and liver-related events in successfully treated patients [5, 24, 25] . In HCV-untreated patients risk of death was significantly higher compared to HCV treated and HIV-monoinfected patients, and also significantly higher compared to treated patients with failure (Fig. 2) . Only about 40% of deaths were liver-related in this group, in line with data from other HIV/HCV cohorts with high extrahepatic mortality rates [23, 26] . The reason for high mortality among untreated patients may be associated with the fact that they mainly belonged to the IDU transmission group, more likely currently injected drugs, reported severe alcohol use, and had less well controlled HIV-infection (Table 1 ). This indicates also that this group may be generally more challenging to treat. These findings underscore the important contribution of social, behavioral and clinical factors associated with increased mortality in HIV/HCV-coinfected patients [23] . Therefore, although curing HCV is an important achievement in the care of these patients, addressing somatic and psychiatric comorbidities is key to reducing mortality in this population.
The proportion of the heterosexual HIV transmission group among patients with active HCV-infection remained approximately stable in the last 13 years, whereas the percentage of IDUs decreased and that of MSM increased. The decrease in the proportion of IDUs can be attributed to successful preventive interventions including methadone substitution and needle exchange programs reducing HCV transmission in this population. Although MSM were more likely to be treated compared to patients from other transmission groups their proportion clearly increased reflecting the rise of incident HCV-infections in MSM in the SHCS which has been previously shown [27] . Despite the increased probability of HCV genotype 3 infected patients to start therapy, the distribution of genotypes did not change noticeably over time.
Major strengths of this study include the large number of patient-years with prospectively collected laboratory and clinical data, regular HCV-screening, and a long follow-up time. Furthermore, the study provides information to physicians and public health authorities on the most urgent needs when planning future HCV interventions in a nationwide representative community based cohort of HIV-infected patients. Our study has several limitations. We did not capture information on contraindications and adverse events of HCV treatment as a reason for deferring therapy or early treatment stop. Another limitation is the lack of vital status information of patients who left the cohort because of very restrictive legislation about linkage with death registries in Switzerland. To account for this limitation we have applied analyses with drop-out as competing risk.
In summary, the long-term assessment of HCV treatment uptake and outcome in this large HIV/HCV-coinfected population revealed a low treatment uptake, which did not increase over time. Treatment efficacy was comparable to results of randomized trials. However, due to the high mortality rate, the number of patients who died was similar to the number of patients who were cured from HCV-infection during follow-up. Most deaths were not liver-related and mortality rate was significantly higher in those who did not start treatment compared to those with treatment failure, indicating that diseases other than HCV are important risk factors for mortality in these patients. By the end of 2013, a large number of HCV-coinfected SHCS participants remain to be treated. Oral DAA therapies with better tolerability, shorter treatment duration and significantly higher efficacy will allow treating many of the difficult-to-treat patients. Interferon-free DAA therapies could overcome most of the treatment barriers identified in our study (Table 2) , including non-3 genotypes, higher age, IDU, low CD4 cell counts and psychiatric disorders. Within the next few years, the extent of the impact of the new treatments on the burden of liver disease in the coinfected population remains to be defined. In this context, our findings underscore the importance of efforts for optimizing care of comorbidities in HIV/HCV-coinfected patients, given that curing HCV alone is not sufficient to achieve mortality rates similar to HIV-monoinfected patients.
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